Jenburkt Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+11.2%+6.9%+3.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+8.0%+22.0%+10.0%
+8.0%+22.0%+10.0%
+8.3%+23.4%+5.6%
+15.2%+18.8%+16.4%
−5.0%+243.5%−52.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

JENBURPH₹872.30

Jenburkt Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue Growth—+3.8+6.9+11.2
EBITDA Growth—+10.0+22.0+8.0
EBIT Growth—+10.0+22.0+8.0
Net Income Growth—+5.6+23.4+8.3
Total Assets Growth—+16.4+18.8+15.2
Cash from Operations Growth—-52.4+243.5-5.0
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.